SCHEMBL24601078

SCHEMBL24601078

CC(C)(C)OC(=O)NCCC1CCN(c2ccnc3[nH]c(=O)ccc23)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 3/20 0.47
SIRT1 Q96EB6 3/20 0.47
SIRT3 Q9NTG7 3/20 0.47
ENPP1 P22413 5/20 0.45
CCNT1 O60563 2/20 0.42
CDK9 P50750 2/20 0.42
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
SUV39H2 Q9H5I1 2/20 0.41
PBK Q96KB5 1/20 0.40
ACACB O00763 2/20 0.39
ACACA Q13085 2/20 0.39
CYP2C9 P11712 1/20 0.38
DRD2 P14416 2/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29691616 1.00 SIRT2 (0.47) SIRT2SIRT1SIRT3ENPP1CCNT1
SCHEMBL24600959 0.91 CKS1B (0.50) ENPP1CKS1BSKP1SKP2SUV39H2
SCHEMBL29691484 0.91 CKS1B (0.50) ENPP1CKS1BSKP1SKP2SUV39H2
SCHEMBL24601106 0.87 ENPP1 (0.41) SIRT2SIRT1SIRT3ENPP1CCNT1
SCHEMBL24600565 0.85 CKS1B (0.48) ENPP1CKS1BSKP1SKP2DRD2
SCHEMBL29691572 0.85 CKS1B (0.48) ENPP1CKS1BSKP1SKP2DRD2
SCHEMBL24600618 0.83 CA12 (0.40) ENPP1CKS1BSKP1SKP2PBK
SCHEMBL26679832 0.80 ENPP1 (0.47) SIRT2SIRT1SIRT3ENPP1PBK
SCHEMBL29691669 0.79 CKS1B (0.40) ENPP1CCNT1CDK9CKS1BSKP1
SCHEMBL24601082 0.79 CKS1B (0.40) ENPP1CCNT1CDK9CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2024-05-02 US disclosed
EP-4276100-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF Txinno Bioscience Inc. (KR) 2023-11-15 EP disclosed
WO-2022146022-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF 주식회사 티씨노바이오사이언스 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF ENPP1, ENPP3, ENTPD5 SIRT2 1397/4885SIRT1 599/4885SIRT3 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.